Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
vNnbQcm2cA8dMFtB